ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
07 Jun 2024
Clinical ResultAHA
FRIDAY, June 7, 2024 -- For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT-2i) are associated with reduced risk of cardiovascular (CV) events compared with dipeptidyl peptidase 4 inhibitors (DPP-4i), according to a study presented at the annual meeting of the Endocrine Society, held from June 1 to 4 in Boston.
Alexander Kutz, M.D., M.P.H., from Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues used pooled data from Medicare fee-for-service and a large U.S. health insurance database to examine the comparative CV and hepatic effectiveness and safety of GLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RA and SLGT-2i in people with T2D and prevalent MASLD.
The researchers found that the hazard ratio (HR) was 0.67 for the primary CV outcome associated with GLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RA (13,666 initiators) versus DPP-4i (17,084 initiators), corresponding to an incidence rate difference (IRD) of −21.6 per 1,000 person-years. For the primary hepatic outcome, the HR was 0.47 and IRD was −2.1. The CV benefits were similar for SGLT-2i (11,108 initiators) versus DPP-4i (16,979 initiators), with a HR of 0.82 for the primary CV outcome and IRD of −11.0. For the primary hepatic outcome, the HR and IRD were not significant. Compared with DPP-4i, severe adverse events did not occur more often with GLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RA or SGLT-2i.
"Our study shows that GLP-1 receptor agonists and SGLT-2 inhibitors are more beneficial in preventing heart-related events compared to another group of drugs such as dipeptidyl peptidase 4 inhibitorsdipeptidyl peptidase 4 inhibitors, and GLP-1s also help reduce severe liver events," Kutz said in a statement.
Press Release
More Information
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.